Core Viewpoint - GoodRx Holdings Inc. (NASDAQ:GDRX) is facing challenges that have led to a downgrade by Jefferies, impacting its stock outlook and price target [1][2]. Group 1: Company Performance - Jefferies downgraded GoodRx from Buy to Hold and reduced the price target from $5.25 to $2.75 [1]. - The company has experienced a 14% year-over-year decline in monthly active consumers and a 9% drop in prescription revenues due to the Rite Aid bankruptcy and the closure of 800 pharmacy locations [1]. - Prescription revenues are expected to remain flat year-over-year, with challenges in the prescription discount segment, which constitutes about 69% of the company's expected revenue [2]. Group 2: Financial Outlook - Analysts project that overall revenue and EBITDA growth for GoodRx will remain muted, leading to stagnant valuation multiples in the short term [2].